| Du, Juan |
NCT06476210: The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB) |
|
|
| Recruiting | 4 | 45 | RoW | BDL regimen | Beijing Chest Hospital, Public Health Clinical Medical Center of Chengdu, Wuhan Institute for Tuberculosis Control, Changsha Central Hospital, Anhui Chest Hospital, Hunan Chest Hospital, Shandong Public Health Clinical Center | Pulmonary Tuberculosis | 06/25 | 06/26 | | |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
PROSPECT, NCT05306223: A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China |
|
|
| Recruiting | 4 | 212 | RoW | Bedaquiline, SIRTURO, Levofloxacin, Linezolid, Cycloserine, Clofazimine, Pyrazinamide, Protionamide | Beijing Chest Hospital | Tuberculosis, Multidrug-Resistant | 08/25 | 08/25 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
INSPIRE-BDLL, NCT06649721: Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort |
|
|
| Not yet recruiting | 3 | 120 | RoW | bedaquiline, BDQ, B, delamanid, DLM, D, linezolid, LZD, L, Levofloxacin, LFX, Clofazimine, CFZ, C | Huashan Hospital, Beijing Chest Hospital | Drug-resistant Tuberculosis, Pulmonary Tuberculosis, Rifampin-resistant Tuberculosis | 06/27 | 06/27 | | |
INSPIRE-CODA, NCT06081361: Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
|
|
| Recruiting | 3 | 186 | RoW | Bedaquiline, BDQ, Delamanid, DLM, Contezolid, CZD, Levofloxacin, LFX, Moxifloxacin, MFX, Clofazimine, CFZ, Linezolid, LZD, Cycloserine, CS, Prothionamide, Pto, Pyrazinamide, PZA, Para-Aminosalicylic Acid, PAS, Ethambutol, EMB | Beijing Chest Hospital, National Medical Center for Infectious Diseases | Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | 10/26 | 12/26 | | |
NCT05634564: Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer |
|
|
| Recruiting | 2 | 62 | RoW | Tislelizumab, Gemcitabine, Nab paclitaxel, Hypofractionated radiotherapy with simultaneous integrated boost | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Carcinoma | 04/23 | 12/23 | | |
NCT06305104: Clinical Trial to Explore the Skin Test Dosage of EEC in People Aged 18 to 65 Years Old and the Safety and Preliminary Efficacy in People Aged 3 to 75 Years Old. |
|
|
| Recruiting | 2 | 420 | RoW | 2.5μg/ml EEC, 5μg/ml EEC, 5 unit（U） EC | Chengdu CoenBiotech Co., Ltd, Beijing Chest Hospital, Capital Medical University, Wuhan Institute for Tuberculosis Control, The Public Health Clinical Center of Chengdu, Xuzhou Infectious Disease Hospital, Jiangsu Province Centers for Disease Control and Prevention, Changde First People's Hospital | Tuberculosis | 05/24 | 06/24 | | |
NCT06389760: Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer |
|
|
| Recruiting | 2 | 57 | RoW | Nimotuzumab, Taixinsheng, mFOLFIRINOX, GX | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Cancer | 09/26 | 09/26 | | |
NCT06224036: Clinical Study of JDB0131 Benzenesulfonate Tablets in Patients With Drug-sensitive Pulmonary Tuberculosis |
|
|
| Recruiting | 2 | 52 | RoW | JDB0131, Delamanid, Ethylpyrazine rifampicide (II) | Beijing Chest Hospital, West China Hospital, Wuhan Pulmonary Hospital (Wuhan Institute For Tuberculosis Control) | Drug-resistant Tuberculosis | 03/24 | 03/24 | | |
PAAG, NCT05493995: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer. |
|
|
| Completed | 2 | 66 | RoW | Penpulimab, AK105, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Pancreatic Neoplasms | 05/24 | 05/24 | | |
CZ-WM01, NCT05979948: A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia |
|
|
| Recruiting | 2 | 60 | RoW | Zanubrutinib, Bendamustine, Rituximab | Shanghai Changzheng Hospital, RenJi Hospital, Huashan Hospital, Shanghai 6th People's Hospital, Huadong Hospital | Waldenström's Macroglobulinemia | 04/25 | 12/25 | | |
RCT-PAAG, NCT06051851: Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer |
|
|
| Recruiting | 2 | 177 | RoW | Penpulimab, Anlotinib, Nab paclitaxel, Gemcitabine | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Adenocarcinoma Metastatic | 07/25 | 07/26 | | |
NCT05594797: Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM |
|
|
| Recruiting | 2 | 100 | RoW | Human BCMA Targeted T Cells Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital, First Affiliated Hospital of Wenzhou Medical University | Multiple Myeloma | 07/25 | 07/27 | | |
NCT04941937: Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM |
|
|
| Recruiting | 2 | 90 | RoW | Selinexor, ATG-010/KPT-330, Thalidomide, fǎn yìng tíng, Lenalidomide, Revlimid, An xian, Pomalidomide, POMALYST, Dexamethasone, Dex | Juan Du | Multiple Myeloma | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 20 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/23 | 07/23 | | |
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 110 | RoW | GC012F | Gracell Biotechnologies Ltd. | Multiple Myeloma | 03/26 | 06/26 | | |
NCT05302648: To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM |
|
|
| Active, not recruiting | 1 | 18 | RoW | Human Derived anti-BCMA CAR-T Injection, BCMA CAR-T | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma | 12/24 | 12/25 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 9 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT06407947: Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 1 | 10 | RoW | Chimeric antigen receptor modified T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma | 06/27 | 06/27 | | |
| Active, not recruiting | 1 | 20 | RoW | Experimental: CAR-T cells Infusion, Single Group Assignment | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Multiple Myeloma, Primary Plasma Cell Leukemia | 07/25 | 07/25 | | |
NCT06718270: a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia |
|
|
| Recruiting | 1 | 24 | RoW | CAR-T cells Infusion | Shanghai Changzheng Hospital, CARsgen Therapeutics Co., Ltd. | Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Plasma Cell Leukemia | 01/27 | 12/27 | | |
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 09/25 | 09/25 | | |
NCT06045091: To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL |
|
|
| Recruiting | 1 | 18 | RoW | Human BCMA targeted CAR-NK cells injection, BCMA CAR-NK | Hrain Biotechnology Co., Ltd., Shanghai Changzheng Hospital | Multiple Myeloma, Plasma Cell Leukemia | 09/25 | 09/27 | | |
NCT04122092: Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma |
|
|
| Recruiting | N/A | 100 | RoW | The level of plasma cfDNA CINs | Shanghai Changzheng Hospital | Multiple Myeloma | 10/21 | 10/22 | | |
NCT06494514: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer |
|
|
| Recruiting | N/A | 40 | RoW | nal-IRI+Oxaliplatin+5-FU/LV+PD-1, Gemcitabine + albumin-paclitaxel+PD-1 | Du Juan | Locally Advanced Pancreatic Cancer | 04/27 | 04/27 | | |
| Lu, Shuihua |
NCT05899179: Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above |
|
|
| Recruiting | 3 | 780 | RoW | Recombinant Mycobacterium Tuberculosis Fusion Protein, EC, Purified Protein Derivative of Tuberculin, TB-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Wuhan Institute for Tuberculosis Control | Latent Tuberculosis Infection | 06/25 | 10/25 | | |
NCT04538911: Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients |
|
|
| Active, not recruiting | 1 | 60 | RoW | BCG-PPD | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Shenzhen Third People's Hospital, Beijing Kangterike Statistical Technology Co., Ltd., Wuhan Pulmonary Hospital | Tuberculosis | 05/23 | 12/25 | | |
NCT06525272: A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With Pleurisy |
|
|
| Not yet recruiting | 1 | 72 | RoW | Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Recombinant Human Chymotrypsin(OsrhCT), Placebo for Recombinant Human Chymotrypsin(OsrhCT), Freeze-dried Powder of Placebo for Recombinant Human Chymotrypsin(OsrhCT) | Healthgen Biotechnology Corp. | Pleurisy | 07/25 | 12/25 | | |
| Chen, Xianxiang |
| No trials found |
